A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin's lymphoma
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms BIORIX
- Sponsors Biocad
- 02 Nov 2017 Status changed from recruiting to completed.
- 01 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.
- 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History